Is Rheumatology Entering the Multiomics Era?
The 52nd Congress of the Spanish Rheumatology Society emphasized the importance of precision medicine in rheumatology, particularly through the use of multiomics and biomarkers. Experts believe that these advancements will lead to more personalized treatment strategies for patients with rheumatic diseases. The integration of various biological systems is seen as crucial for improving patient outcomes and tailoring therapies effectively.
- ▪The Congress highlighted a shift toward precision medicine in rheumatology.
- ▪Experts discussed the role of multiomics and biomarkers in developing personalized treatment strategies.
- ▪Advances in fibroblast research are expected to influence future therapeutic targets in medicine.
Medscape files mainly under health. We currently carry 231 of its stories.
Story provenance
Source · retrieval · rights · ranking — open for full record
inspect →
Story provenance
Attribution is not the same as permission. This drawer separates discovery metadata, excerpts, WeSearch-generated summaries, reuse status, and whether the publisher receives the visit. Nothing here claims a legal grant the publisher has not made.
Record
| Original publisher | Medscape |
| Canonical URL | https://www.medscape.com/viewarticle/rheumatology-entering-multiomics-era-2026a1000gfu?src=rss |
| Publication time | Thu, 21 May 2026 03:02:27 EDT |
| Retrieval time | 2026-05-21T07:05:03.555Z |
| Last seen | 2026-05-21T07:05:03.555Z |
| Headline source | Publisher (no WeSearch rewrite) |
| Excerpt source | publisher body |
| Excerpt method | First ~120 words (~800 chars) of extracted publisher body, fair-use limited. |
| Summary | WeSearch · cerebras-chat (WeSearch summarizer) |
| Summary source text | contentText |
| Citation coverage | Summary is a WeSearch-generated derivative; primary citation is the original publisher URL. |
| Cluster | TlcoDoEFTFGs |
| Cluster logic | Grouped by semantic title/content similarity across sources within a rolling window. Same-publisher template collisions are excluded from coverage comparison. |
| Ranking reason | Story pages are not engagement-ranked. Hub feeds use recency, with optional source-diversified chronological ordering (cap consecutive stories per source). No personalized ranking. |
| Publisher visit | Yes — open original |
| Substitutes article? | No — link-out required for full text |
Rights status (four layers)
WeSearch handling by dimension
| Indexing | May the item be indexed (stored, ranked, made findable)? | Allowed |
| Snippet | May a short excerpt of the publisher's text be shown? | Allowed |
| AI summary | May WeSearch generate its own short summary of the article? | Limited |
| Retrieval / RAG | May the content be exposed for third-party retrieval-augmented generation? | Not asserted |
| Model training | May the content be used to train AI models? | Not asserted |
| Commercial reuse | May the content be reused commercially? | Not permitted |
Basis: Derived from the published RSS/Atom feed. Contact: [email protected]. Reviewed: 2026-07-24.
Opening excerpt (first ~120 words) tap to expand
The 52nd Congress of the Spanish Rheumatology Society (SER) in Bilbao, Spain, highlighted a shift toward precision medicine in rheumatology, with experts pointing to multiomics, biomarkers, and targeted therapies as key tools expected to shape more personalized treatment strategies and future clinical practice. Natividad Oreiro Villar, MD, PhD, from the Rheumatology Department at the University Hospital Complex of A Coruña, A Coruña, Spain, said, “We need to bring rheumatology closer to personalized medicine.
…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Medscape.
Discussion
0 commentsMore from Medscape
